LIVIVO - The Search Portal for Life Sciences

zur deutschen Oberfläche wechseln
Advanced search

Search results

Result 1 - 10 of total 222

Search options

  1. Article ; Online: Structural cell heterogeneity underlies the differential contribution of IL-17A, IL-17F and IL-23 to joint versus skin chronic inflammation.

    Robert, Marie / Miossec, Pierre

    Autoimmunity reviews

    2024  Volume 23, Issue 4, Page(s) 103529

    Abstract: The current therapeutic strategy used in immune-mediated inflammatory diseases (IMIDs) primarily targets immune cells or associated-pathways. However, recent evidence suggests that the microenvironment modulates immune cell development and responses. ... ...

    Abstract The current therapeutic strategy used in immune-mediated inflammatory diseases (IMIDs) primarily targets immune cells or associated-pathways. However, recent evidence suggests that the microenvironment modulates immune cell development and responses. During inflammation, structural cells acquire a pathogenetic phenotype and the interactions with immune cells are often greatly modified. Understanding the importance of these tissue-specific interactions may allow to explain why some biologics are effective in some IMIDs but not in others. The differential effects of interleukin (IL)-17 A, IL-17F and IL-23 in joint versus skin inflammation depends on structural cell heterogeneity. In addition, the sometimes opposite effects of immune/structural cell interactions on the production of these cytokines illustrate the importance of these cells in chronic inflammation, using the examples of rheumatoid arthritis, psoriasis and spondyloarthritis. This review describes these concepts, shows their interests through clinical observations, and finally discusses strategies to optimize therapeutic strategies.
    Language English
    Publishing date 2024-03-15
    Publishing country Netherlands
    Document type Journal Article ; Review
    ZDB-ID 2144145-5
    ISSN 1873-0183 ; 1568-9972
    ISSN (online) 1873-0183
    ISSN 1568-9972
    DOI 10.1016/j.autrev.2024.103529
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  2. Article ; Online: Local and systemic effects of IL-17 in joint inflammation: a historical perspective from discovery to targeting.

    Miossec, Pierre

    Cellular & molecular immunology

    2021  Volume 18, Issue 4, Page(s) 860–865

    Abstract: The role of IL-17 in many inflammatory and autoimmune diseases is now well established, with three currently registered anti-IL-17-targeted therapies. This story has taken place over a period of 20 years and led to the demonstration that a T cell product ...

    Abstract The role of IL-17 in many inflammatory and autoimmune diseases is now well established, with three currently registered anti-IL-17-targeted therapies. This story has taken place over a period of 20 years and led to the demonstration that a T cell product could regulate, and often amplify, the inflammatory response. The first results described the contribution of IL-17 to local features in arthritis. Then, understanding was extended to its systemic effects, with a focus on cardiovascular aspects. This review provides a historical perspective of these discoveries focused on arthritis, which started in 1995, followed 10 years later by the description of Th17 cells. Today, IL-17 inhibitors for three chronic inflammatory diseases have been registered. More options are now being tested in ongoing and future clinical trials. Inhibitors of IL-17 family members and Th17 cells ranging from antibodies to small molecules are under active development. The identification of patients with IL-17-driven disease is a key target for the improved selection of patients expected to have a strongly positive response.
    MeSH term(s) Animals ; Antibodies, Monoclonal/therapeutic use ; Arthritis, Rheumatoid/drug therapy ; Arthritis, Rheumatoid/immunology ; Arthritis, Rheumatoid/metabolism ; Arthritis, Rheumatoid/pathology ; Humans ; Inflammation/drug therapy ; Inflammation/immunology ; Inflammation/metabolism ; Inflammation/pathology ; Interleukin-17/antagonists & inhibitors ; Joint Diseases/drug therapy ; Joint Diseases/immunology ; Joint Diseases/metabolism ; Joint Diseases/pathology ; Molecular Targeted Therapy ; Small Molecule Libraries/therapeutic use
    Chemical Substances Antibodies, Monoclonal ; Interleukin-17 ; Small Molecule Libraries
    Language English
    Publishing date 2021-03-10
    Publishing country China
    Document type Journal Article ; Review
    ZDB-ID 2435097-7
    ISSN 2042-0226 ; 1672-7681
    ISSN (online) 2042-0226
    ISSN 1672-7681
    DOI 10.1038/s41423-021-00644-5
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  3. Article: Understanding the cytokine storm during COVID-19: Contribution of preexisting chronic inflammation.

    Miossec, Pierre

    European journal of rheumatology

    2020  Volume 7, Issue Suppl 2, Page(s) S97–S98

    Keywords covid19
    Language English
    Publishing date 2020-05-11
    Publishing country Turkey
    Document type Journal Article
    ZDB-ID 2873727-1
    ISSN 2148-4279 ; 2147-9720
    ISSN (online) 2148-4279
    ISSN 2147-9720
    DOI 10.5152/eurjrheum.2020.2062
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  4. Article ; Online: Synergy Between Cytokines and Risk Factors in the Cytokine Storm of COVID-19: Does Ongoing Use of Cytokine Inhibitors Have a Protective Effect?

    Miossec, Pierre

    Arthritis & rheumatology (Hoboken, N.J.)

    2020  Volume 72, Issue 12, Page(s) 1963–1966

    MeSH term(s) COVID-19/blood ; COVID-19/complications ; Cytokine Release Syndrome/blood ; Cytokine Release Syndrome/etiology ; Cytokine Release Syndrome/prevention & control ; Cytokines/blood ; Humans ; Interleukin-6/antagonists & inhibitors
    Chemical Substances Cytokines ; Interleukin-6
    Keywords covid19
    Language English
    Publishing date 2020-10-15
    Publishing country United States
    Document type Editorial
    ZDB-ID 2756371-6
    ISSN 2326-5205 ; 2326-5191
    ISSN (online) 2326-5205
    ISSN 2326-5191
    DOI 10.1002/art.41458
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  5. Article ; Online: Heterogeneous effects of S100 proteins during cell interactions between immune cells and stromal cells from synovium or skin.

    Noack, Mélissa / Miossec, Pierre

    Clinical and experimental immunology

    2023  Volume 212, Issue 3, Page(s) 276–284

    Abstract: Cell interactions represent an important mechanism involved in the pathogenesis of chronic inflammation. The key S100 proteins A8 and A9 have been studied in several models of chronic inflammatory diseases with highly heterogeneous conclusions. In this ... ...

    Abstract Cell interactions represent an important mechanism involved in the pathogenesis of chronic inflammation. The key S100 proteins A8 and A9 have been studied in several models of chronic inflammatory diseases with highly heterogeneous conclusions. In this context, the aim of this study was to determine the role of cell interactions on S100 protein production and their effect on cytokine production during cell interactions, between immune and stromal cells from synovium or skin. Peripheral blood mononuclear cells (PBMC) were cultured alone or with synoviocytes or skin fibroblasts, with or without phytohemagglutinin, exogenous A8, A9, A8/A9 proteins or anti-A8/A9 antibody. Production of IL-6, IL-1β, IL-17, TNF, A8, A9, and A8/A9 was measured by ELISA. Cell interactions with synoviocytes had no effect on A8, A9, or A8/A9 secretion, while cell interactions with skin fibroblasts decreased A8 production. This highlights the importance of stromal cell origin. The addition of S100 proteins in co-cultures with synoviocytes did not increase the production of IL-6, IL-17, or IL-1β, except for an increase of IL-6 secretion with A8. The presence of anti-S100A8/A9 antibody did not show obvious effects. Low concentration or absence of serum in the culture medium decreased the production of IL-17, IL-6, and IL-1β but despite these conditions, the addition of S100 proteins did not increase cytokine secretion. In conclusion, the role of A8/A9 in cell interactions during chronic inflammation appears complex and heterogeneous, depending on multiple factors, notably the origin of stromal cells that can affect their secretion.
    MeSH term(s) Humans ; Interleukin-17/metabolism ; Leukocytes, Mononuclear ; Calgranulin B/metabolism ; S100 Proteins/metabolism ; Interleukin-6/metabolism ; Synovial Membrane/metabolism ; Inflammation/metabolism ; Cell Communication
    Chemical Substances Interleukin-17 ; Calgranulin B ; S100 Proteins ; Interleukin-6
    Language English
    Publishing date 2023-03-02
    Publishing country England
    Document type Journal Article ; Research Support, Non-U.S. Gov't
    ZDB-ID 218531-3
    ISSN 1365-2249 ; 0009-9104 ; 0964-2536
    ISSN (online) 1365-2249
    ISSN 0009-9104 ; 0964-2536
    DOI 10.1093/cei/uxad035
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  6. Article ; Online: Understanding the cytokine storm during COVID-19

    Pierre Miossec

    European Journal of Rheumatology, Vol 7, Iss -2, Pp S97-S

    Contribution of preexisting chronic inflammation

    2020  Volume 98

    Keywords Immunologic diseases. Allergy ; RC581-607 ; covid19
    Language English
    Publishing date 2020-08-01T00:00:00Z
    Publisher AVES Yayincilik
    Document type Article ; Online
    Database BASE - Bielefeld Academic Search Engine (life sciences selection)

    More links

    Kategorien

  7. Article: Réactivation de la tuberculose au cours des traitements par inhibiteurs du TNF.

    Miossec, Pierre

    La Revue du praticien

    2019  Volume 68, Issue 5, Page(s) 537–540

    Abstract: Reactivation of tuberculosis during treatment with inhibitors of TNF. The inhibition of the tumor necrosis factor (TNF) has been a major progress in the treatment of chronic inflammatory diseases by acting on their local and systemic manifestations. ... ...

    Title translation Reactivation of tuberculosis during treatment with inhibitors of TNF.
    Abstract Reactivation of tuberculosis during treatment with inhibitors of TNF. The inhibition of the tumor necrosis factor (TNF) has been a major progress in the treatment of chronic inflammatory diseases by acting on their local and systemic manifestations. However, this treatment can be responsible for severe infections, specifically reactivation of tuberculosis. The underlying mechanisms of these infections in this context are now better understood. First, chronic inflammatory diseases are associated with a cellular mediated immune defect, specifically affecting the Th1 pathway. On the other hand, TNF has a central role in granuloma formation. TNF inhibition allows the escape of tuberculosis bacillus from residual sites and its rapid diffusion. This understanding has allowed the implementation of prevention measures with screening and treatment of latent tuberculosis.
    MeSH term(s) Humans ; Latent Tuberculosis/diagnosis ; Latent Tuberculosis/therapy ; Mycobacterium tuberculosis ; Tuberculosis/diagnosis ; Tuberculosis/therapy ; Tumor Necrosis Factor-alpha
    Chemical Substances Tumor Necrosis Factor-alpha
    Language French
    Publishing date 2019-04-03
    Publishing country France
    Document type Journal Article
    ZDB-ID 205365-2
    ISSN 2101-017X ; 0035-2640
    ISSN (online) 2101-017X
    ISSN 0035-2640
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  8. Article ; Online: Inflammation in 2017: Connectivity to other fields brings new ideas.

    Miossec, Pierre

    Nature reviews. Rheumatology

    2018  Volume 14, Issue 2, Page(s) 65–66

    MeSH term(s) Animals ; Anti-Citrullinated Protein Antibodies/metabolism ; Arthritis, Rheumatoid/etiology ; Arthritis, Rheumatoid/immunology ; Communicable Diseases/immunology ; Comorbidity ; Humans ; Inflammation/metabolism ; Interleukin-1/metabolism
    Chemical Substances Anti-Citrullinated Protein Antibodies ; Interleukin-1
    Language English
    Publishing date 2018-01-11
    Publishing country United States
    Document type Journal Article ; Research Support, Non-U.S. Gov't ; Review
    ZDB-ID 2491532-4
    ISSN 1759-4804 ; 1759-4790
    ISSN (online) 1759-4804
    ISSN 1759-4790
    DOI 10.1038/nrrheum.2017.215
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  9. Article: Synergy Between Cytokines and Risk Factors in the Cytokine Storm of COVID-19: Does Ongoing Use of Cytokine Inhibitors Have a Protective Effect?

    Miossec, Pierre

    Arthritis rheumatol. (Malden. Online)

    Keywords covid19
    Publisher WHO
    Document type Article
    Note WHO #Covidence: #871335
    Database COVID19

    Kategorien

To top